{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"tesamorelin","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tesamorelin/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"tesamorelin","title":"tesamorelin","register":"standard","tags":[],"updated_at":"2026-07-17T02:42:19.974Z","body_excerpt":"## Overview\nEvidence is being populated by Grok web search.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","summary":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","summary":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","summary":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","summary":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","summary":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"853bbca219795e5e5a1825104340e3c7020244c0910c40ee6861ceb960cf1b90"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","summary":"2026 meta-analysis of RCTs concluding tesamorelin benefits body composition and hepatic fat in HIV lipodystrophy with favorable safety.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"deafc06c6a5f7dd98046e0b6a03e987a26199afe00bced2939cfbffb562e4a2a"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","summary":"2025 clinical study on tesamorelin effects on neurocognitive impairment in HIV patients with abdominal obesity.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"55299462964e592ea141f1e0dc057b544541bcbbfc813ba0e518e9a99671f493"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","summary":"Ongoing 2026 Phase 2 trial evaluating tesamorelin plus exercise in HIV patients for physical function and muscle health.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"6de042dc8ae1370de1f77c3484269d514dbb51fb7a337c1117e3fb8e6a339c99"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","summary":"2024 subanalysis of RCT showing tesamorelin reduces visceral fat, hepatic fat, and improves fat distribution in HIV patients on integrase inhibitors, well-tolerated.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"66cdb2a41d7ebb7b1d409e1b48f6d5cd17e0858f7c8c16ba81fd9f424b989abb"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","summary":"New 2026 Phase II trial protocol for tesamorelin in MASLD/NAFLD.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"853bbca219795e5e5a1825104340e3c7020244c0910c40ee6861ceb960cf1b90"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"tesamorelin","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":5,"anecdotal":0,"scientific":5,"user_reports":0,"questions":0,"evidence_ingests":0}}